United Therapeutics Upgraded to Outperform at Zacks (UTHR)
United Therapeutics (NASDAQ:UTHR) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report issued on Thursday. The firm currently has a $112.00 price target on the stock. Zacks‘s target price indicates a potential upside of 20.17% from the stock’s previous close.
Zacks’ analyst wrote, “United Therapeutics’ second quarter 2014 EPS was better than expected at $2.10. This was well above the Zacks Consensus Estimate of $1.66 and the year-ago EPS of $1.52. Revenues, which increased 15% to $322.8 million, surpassed the Zacks Consensus Estimate of $311 million. Revenues benefited from the continued uptake of existing products and the launch of Orenitram. The company remains well-positioned to gain share in the PAH market and estimates for 2014 and 2015 are on the rise following the strong second quarter performance. Based on these factors, we are upgrading United Therapeutics to Outperform.”
United Therapeutics (NASDAQ:UTHR) traded up 0.12% on Thursday, hitting $93.3795. The stock had a trading volume of 212,480 shares. United Therapeutics has a 52-week low of $70.34 and a 52-week high of $116.65. The stock’s 50-day moving average is $91.29 and its 200-day moving average is $95.55. The company has a market cap of $4.414 billion and a price-to-earnings ratio of 18.02.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, July 29th. The company reported $2.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter last year, the company posted $1.52 earnings per share. United Therapeutics’s revenue was up 15.0% compared to the same quarter last year. On average, analysts predict that United Therapeutics will post $8.55 earnings per share for the current fiscal year.
UTHR has been the subject of a number of other recent research reports. Analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday, July 31st. Separately, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Finally, analysts at HC Wainwright raised their price target on shares of United Therapeutics from $120.00 to $150.00 in a research note on Wednesday, July 30th. They now have a “buy” rating on the stock. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $102.87.
In other United Therapeutics news, Director Christopher Causey sold 1,500 shares of the company’s stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of $91.14, for a total transaction of $136,710.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.